Skip to main content
SpringerLink
Log in

Substantial cost savings can result from the use of losartan in patients with type 2 diabetes mellitus (T2DM) and nephropathy,

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Sarafidis PA, Stafylas PC, Lasaridis AN, Grekas DM, Dombros NV, Tsakni E, Aletras VH, Niakas DA, Bakris GL.Cost-effectiveness of losartan in the treatment of patients with type 2 diabetes and nephropathy in Greece. Journal of Hypertension 24 (Suppl. 4): 140, Jun 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Substantial cost savings can result from the use of losartan in patients with type 2 diabetes mellitus (T2DM) and nephropathy,. Pharmacoecon. Outcomes News 511, 8 (2006). https://doi.org/10.2165/00151234-200605110-00021

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605110-00021

Keywords

Search

Navigation